OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
OCULAR THERAPEUTIX, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$6.29−0.58 (-8.44%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
OCULAR THERAPEUTIX, INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $13.48M | $10.79M | $13.25M | $14.54M | $13.40M | $10.63M | $17.02M | $15.35M | $16.38M | $14.72M | $14.68M | $14.95M | 100.0% | +0.6% |
| Collaboration revenue | – | – | $0 | $0 | $64.00K | $64.00K | $62.00K | $78.00K | $62.00K | $59.00K | $124.00K | $131.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Ocular Therapeutix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.